The purpose of this study is to evaluate the efficacy and safety of repeated doses of a low dosage of oromucosal Ibuprofen form (lozenge) versus placebo in patients suffering from acute sore throat pain.

Inclusion Criteria:

• male or female aged at least 18 years old
• patient with an acute sore throat

Exclusion Criteria:

• Severe respiratory tract infection (pneumonia, bronchitis or laryngitis)
• Oro-pharyngeal paresthesia or mycosis
• Severely traumatised and/or very severe oromucosal inflammation
• Tonsillopharyngectomy
• Peritonsillar abscess
• Hypersensitivity to ibuprofen or other NonSteroidal Anti-Inflammatory Drugs (NSAIDs) (including bronchospasm) or to excipients
• Long term use (≥ 3 times per week within the last month or regular intake within the last 3 months before randomisation) of antiinflammatory drugs- Any long-acting or slow release analgesic intake including NonSteroidal Anti-Inflammatory Drugs (NSAIDs)within 24 hours before randomisation (e.g. piroxicam or naproxen)
• Any anti-inflammatory drugs intake by systemic route within 12 hours before randomisation
• Any paracetamol intake within 6 hours before randomisation
• Any cold medication (decongestant, antihistamine, expectorant, antitussive) within 6 hours before randomisation
• Any topical throat medication intake containing or not a local oral anaesthetic such as lozenge, spray, mouth rinse within 4 hours before randomisation
• Heavy smokers (>20 cigarettes/day)